Recent research has shown that we may be able to identify AMD-affected individuals even earlier by testing for impaired dark adaptation. Learn how this discovery can translate to early detection and intervention of age-related macular degeneration.
New results show promise that AREDS2 may be an effective treatment in IMT2 in addition to age-related macular degeneration. Here's what you need to know about the off-label uses of AREDS2.
Relative afferent pupillary defect testing focuses on the afferent light pathway and can play an integral part of clinical testing. Here are two effective testing techniques.
If you're considering working for a corporation or subleasing an office, make sure you know whether you'll be working in a one-door or a two-door state. These laws regulate the separation—or lack thereof—between your office space and the adjacent store.
In addition to ocular problems associated with hepatitis C, we should also be concerned with the side effects of treatment. What can you, as an optometrist, do to better treat your patients systemically?
Explaining ocular disease to your patients can be difficult. Here are 5 things to keep in mind when educating patients.